Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.

@article{Sorror2011LongtermOA,
  title={Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.},
  author={Mohamed L Sorror and Brenda M Sandmaier and Barry E Storer and Georg Nikolaus Franke and Ginna G. Laport and Thomas R Chauncey and Edward D Agura and Richard T Maziarz and Amelia A. Langston and Parameswaran N. Hari and Michael A Pulsipher and Wolfgang Andreas Bethge and Firoozeh Sahebi and Benedetto Bruno and Michael B. Maris and Andrew M. Yeager and Finn Bo Petersen and Lars Lindhardt Vindel\ov and Peter A. Mcsweeney and Kai H{\"u}bel and Marco Mielcarek and George E Georges and Dietger Niederwieser and Karl G. Blume and David G Maloney and Rainer F Storb},
  journal={JAMA},
  year={2011},
  volume={306 17},
  pages={1874-83}
}
CONTEXT A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic malignancies who are older or have comorbid conditions. OBJECTIVE To describe outcomes of patients 60 years or older after receiving minimally toxic nonmyeloablative allogeneic HCT. DESIGN, SETTING, AND PARTICIPANTS From 1998 to 2008, 372 patients aged 60 to 75 years were enrolled in prospective clinical HCT trials at 18… CONTINUE READING